Hey! I'm still here but I've been lately spending my time building something new: https://t.co/g52APB1LZi. In a nutshell, CapRelay is an equity research platform that thoughtfully leverages AI. Here's the announcement from my "main" accnt:
Hi! back online to announce that @chi_s0ng and I are excited to launch CapRelay! https://t.co/45gp1OR2Rc is an equity research platform that thoughtfully uses AI to help analysts get up to speed on companies and uncover new insights / risks / interesting opportunities.
Judging from headlines, concern seems to have stabilized / eased off a bit. I'm not a private credit doomer by any means, but it pays to continue to monitor PC and alt inv. risks to annuity writers at this point in the cycle... A snippet of some recent exploration $FG $BNT
Chatbot this, chatbot that. Think this is probably the highest leverage way to use AI for inv research - have agents churn through and analyze things at scale (I'm obvs biased but I think it's also 10x better combined with a high-quality data/research source)
Fun fact - AI agents are now 30%+ of all of CapRelay's usage!
In the video ⬇️, my CapRelay co-founder @chi_s0ng demonstrates how you can use Claude Code with CapRelay to generate high-quality summaries of the AI-specific bear cases for all $2B+ market cap software companies:
At a hedge fund I worked at, we were investors in TransDigm for years. I always wondered what other companies were running a similar playbook.
If you're a professional investor, you're also probably always looking for new expressions of your big winners.
Today, CapRelay is making this process of pattern-matching fast, with a new feature that instantly surfaces similar theses to every US-listed company.
The 90-second walkthrough shows the highlights ⬇️
(This isn't to say you shouldn't tread carefully and think about how truly long duration each company's liabilities are and who can best ride out heightened headline risks or that there won't be credit-related risks to watch out for)
@barronsonline and anyone else interested in REITs, hit me up to try https://t.co/45gp1OR2Rc out :) - the difference in business models between $CTRE and $WELL and growth can be seen easily in our business overviews and multi-year recaps. For example, for $CTRE:
Introducing CapRelay, the fastest way to find and iterate through ideas
Do you want click through buy-side bull-bear debates on every US-listed company, with no load times or prompt bars? Or screen based on your qualitative investment criteria, like cos with limited competition?
(Oh and at some point, I'd also like to opine on private credit and AI & software too - there's a lot of opinions flying around, but I feel like it sits at a pretty neat intersection of a lot of my interests haha...)
Hey! I'm still here but I've been lately spending my time building something new: https://t.co/g52APB1LZi. In a nutshell, CapRelay is an equity research platform that thoughtfully leverages AI. Here's the announcement from my "main" accnt:
Hi! back online to announce that @chi_s0ng and I are excited to launch CapRelay! https://t.co/45gp1OR2Rc is an equity research platform that thoughtfully uses AI to help analysts get up to speed on companies and uncover new insights / risks / interesting opportunities.
If you've read this far, I'd welcome you to sign up for a free trial at https://t.co/aidU2JS0EB and would love to hear any feedback or questions! Follow us along at @CapRelayHQ too
@GuyImpatient I've kind of thought of it as neutral for them at least in short-term given they source a lot of Chinese UCO currently. That said, I think this makes domestic UCO that much more valuable and they are in a great position to source a lot of it. Guessing that's your take as well?
@DannyOcean555 Lest I seem too bullish, I think mgmt is pretty meh overall esp. in their pretty weak defense against Aya's encroachment, only ok-ish tech, and terrible capital allocation (hindsight is of course 20/20 but geez...). Still, think this is an interesting one! thanks
@DannyOcean555 Another point to consider / interested in your thoughts on. Nurse shortages look like it will continually persist for years - I think the tight supply there is pretty favorable as there will prob be future shortages that give $AMN and its peers a reason to exist